Latest News

• 03 Feb 2021 – Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel
• 02 Feb 2021 – Destiny Pharma to join panel discussion at the 7th Annual LSX World Congress 2021
• 02 Feb 2021 – Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board
• 27 Jan 2021 – Destiny Pharma welcomes Matt Hancock’s statement saying G7 will focus on AMR
• 21 Jan 2021 – Destiny Pharma Investor Presentation
• 06 Jan 2021 – Destiny Pharma appoints Stephanie Bewick as Chief Business Officer
• 05 Jan 2021 – Phase 2b trial of XF-73 completes recruitment
• 22 Dec 2020 – Update on the recently acquired NTCD-M3 programme
• 21 Dec 2020 – Destiny Pharma joins the Pharmabiotic Research Institute (PRI)
• 26 Nov 2020 – Destiny Pharma – Result of General Meeting and Total Voting Rights